Latest News in the pharma Industry

Biopharma News

ProJect Pharmaceutics expands facilities for formulation and lyophilization process development

ProJect Pharmaceutics expands facilities for formulation and lyophilization process development

28 Feb 2018

Expansions to meet safety requirements for GMO S2 and BSL-2 biological products.

Read more 
Revolutionary downstream bioconjugation method under development

Revolutionary downstream bioconjugation method under development

12 Feb 2018

New manufacturing paradigm will save 25% of total costs and the need for proteinaceous A & G resins.

Read more 
A powerful new tool for the separation of charged species

A powerful new tool for the separation of charged species

4 Feb 2018

A new analytical tool, Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) is showing much promise in biopharmaceutical and nanoparticle applications.

Read more 
New Pall business unit launches to focus on end-to-end drug manufacturing models

New Pall business unit launches to focus on end-to-end drug manufacturing models

31 Jan 2018

Pall Biotech to focus on enabling drug manufacturers to rapidly transition from pre-clinical to commercial manufacturing.

Read more 
Ablynx - Sanofi's new acquisition

Ablynx - Sanofi's new acquisition

29 Jan 2018

Strengthens Sanofi's R&D strategy with innovative Nanobody technology platform.

Read more 
Sandoz and Biocon to collaborate on next-generation biosimilars

Sandoz and Biocon to collaborate on next-generation biosimilars

19 Jan 2018

Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars.

Read more 
SSB to equip Abzena's US-based development and manufacturing sites

SSB to equip Abzena's US-based development and manufacturing sites

4 Jan 2018

SSB will provide both facilities with end-to-end process solutions in single-use format.

Read more 
Momenta and Mylan to development proposed biosimilar to Eylea

Momenta and Mylan to development proposed biosimilar to Eylea

4 Jan 2018

Targeting the initiation of a pivotal patient clinical trial in the first half of 2018.

Read more 
ANVISA approves Biocon and Mylan's biosimilar Trastuzumab

ANVISA approves Biocon and Mylan's biosimilar Trastuzumab

29 Dec 2017

Libbs will commercialize the product in Brazil under the brand name Zedora.

Read more 
Major changes for bio supply forecast in 2018 by bioLIVE

Major changes for bio supply forecast in 2018 by bioLIVE

19 Dec 2017

Integration of supply chain a critical issue as industry globalises, with a resurgence in European manufacturing and biotech markets forecast.

Read more 
Hikma signs licensing agreement with Celltrion for third biosimilar product in MENA region

Hikma signs licensing agreement with Celltrion for third biosimilar product in MENA region

19 Dec 2017

Truxima is mAb biosimilar to Roche's MabThera (rituximab).

Read more 
CMC Biologics and Harpoon Therapeutics collaborate on exciting new TriTAC molecules

CMC Biologics and Harpoon Therapeutics collaborate on exciting new TriTAC molecules

14 Dec 2017

First clinical candidate, HPN424, is in development for the treatment of metastatic prostate cancer and expected to enter Phase I clinical trials in 2018.

Read more